Table 2. Twenty distinct circulating metabolites between malignant mesothelioma patients and healthy controls were annotated.

No.	Metabolite	VIPa	p-valueb	FCc	AUCd
1	Butane-2,3-diol	4.03	9.67E−04	0.04	0.86
2	3-hydroxypropionic acid	3.51	1.88E−03	2.18	0.83
3	(s)-3,4-dihydroxybutyric acid	2.27	7.24E−07	2.22	0.95
4	Gluconic acid	2.26	1.75E−03	2.7	0.92
5	Xanthurenic acid	2.24	8.29E−10	0.53	0.96
6	Beta-d-glucopyranuronic acid	2.04	1.01E−04	2.13	0.92
7	Taurine	1.98	1.15E−03	2.78	0.78
8	Aconitic acid	1.94	6.33E−07	1.8	0.89
9	4-aminobutyric acid	1.93	1.52E−04	2.06	0.88
10	L-histidine	1.91	6.18E−03	0.6	0.79
11	Glycocyamine	1.86	5.77E−06	0.59	0.86
12	Allantoic acid	1.84	1.72E−02	2.87	0.77
13	Azelaic acid	1.82	2.70E−04	2.12	0.83
14	2-monoolein	1.76	1.30E−04	2.07	0.82
15	N-carbamoylaspartate	1.74	4.13E−03	0.5	0.77
16	L-2-hydroxyglutaric acid	1.72	3.92E−04	1.65	0.86
17	Glyceric acid	1.64	1.64E−03	1.67	0.83
18	D-arabinose	1.62	4.43E−03	1.72	0.92
19	Glucose	1.6	3.98E−04	1.97	0.74
20	L-glutamic acid	1.52	5.39E−03	1.68	0.74

Notes:

^aVariable importance in the projection of OPLS-DA model.

^bFrom two-tailed Student’s t-test test.

^cFold change (MM vs control).

^dThe area under ROC curve.